ALLR Latest Press Releases

-- April 21, 2026 --

Allarity Therapeutics Presents Two AACR 2026 Posters Highlighting Stenoparib's Potential in Colorectal Cancer as well as New Predictive Data Linking DRP and Overall Survival in Ovarian Cancer Globe Newswire 8:00 AM

-- March 31, 2026 --

Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress Globe Newswire 8:00 AM

-- March 6, 2026 --

Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization Globe Newswire 8:00 AM

-- February 18, 2026 --

Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need Globe Newswire 8:15 AM

-- February 3, 2026 --

Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran's Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment Globe Newswire 8:00 AM

-- December 31, 2025 --

Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders Globe Newswire 8:00 AM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software